Partnership Powerhouse LDC maintains a broad ecosystem of alliances with major pharma players and leading academic translational centers, including collaborations with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Roche and industry innovators, plus recent ties with IfADo and Taros. This network provides credible deal flow and a solid foundation for joint development programs.

KyDo Tech Licensing The KyDo platform, developed through academia and expanded with industry partners, is being advanced into drug discovery programs. This differentiated technology offers opportunities for licensing or co development to biotech and pharma entities seeking accelerated hit generation and lead optimization.

End-to-End Discovery LDC offers an integrated small molecule discovery platform encompassing automation and screening, cellular biology, pharmacology, medicinal chemistry and antibody discovery to convert early ideas into lead candidates with animal proof of concept. This enables customers to outsource end to end discovery and shorten timelines.

Credible Track Record A history of academic and biotech collaborations with universities and institutes, and partnerships with investment and biotech players, demonstrates LDCs credibility in managing early stage assets across therapeutic areas and geographies. This reduces risk for potential partners and accelerates collaboration onboarding.

Growth and Capacity With a mid sized team and solid revenue, LDC is positioned to scale its discovery services to accommodate growing partner pipelines. The combination of strong tech stack and global collaborations supports expanding program capacity and multi project engagements.